Therapeutic Asset Ratings
122 results matching 1 filter
133,990 assets · 8,802 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Etavopivat
Sickle Cell Disease
Novo Nordisk A/S
P3
B
(60)
L-Citrulline
Sickle Cell Disease
Asklepion Pharmaceuticals, LLC
P3
B
(60)
IBUPROFEN
Sickle Cell Disease
Cairo University
P4
B
(59)
Metformin
Sickle Cell Disease
Pfizer
P2
B
(59)
Rapamycin
Sickle Cell Disease
St. Jude Children's Research Hospital
P2
B
(59)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Sickle Cell Disease
Columbia University
P2
B
(58)
Rabbit Anti-Thymocyte Globulin
Sickle Cell Disease
Emory University
P2
B
(58)
Folic Acid
Sickle Cell Disease
Indiana University
P2/3
B
(58)
Ketorolac Tromethamine
Sickle Cell Disease
Children's Blood and Cancer Center at Dell Children's Medical Center
P4
B
(57)
Voxelotor
Sickle Cell Disease
Inova Health Care Services
P4
B
(57)
DEXAMETHASONE
Sickle Cell Disease
Nantes University Hospital
P3
B
(57)
Plerixafor
Sickle Cell Disease
Hospital Israelita Albert Einstein
P2
B
(57)
DEXKETOPROFEN
Sickle Cell Disease
Emory University
P4
B
(56)
METAMIZOLE
Sickle Cell Disease
Emory University
P4
B
(56)
Nexplanon
Sickle Cell Disease
University of Pennsylvania
P4
B
(56)
LIDOCAINE
Sickle Cell Disease
Nantes University Hospital
P3
B
(56)
Meperidine
Sickle Cell Disease
Nantes University Hospital
P3
B
(56)
Methylphenidate
Sickle Cell Disease
St. Jude Children's Research Hospital
P3
B
(56)
Senicapoc
Sickle Cell Disease
Biossil Inc.
P3
B
(56)
ABATACEPT RECOMBINANT
Sickle Cell Disease
St. Jude Children's Research Hospital
P2
B
(56)
Decitabine
Sickle Cell Disease
Novo Nordisk A/S
P2
B
(56)
Losartan
Sickle Cell Disease
Children's Hospital Medical Center, Cincinnati
P2
B
(56)
Equine Atg
Sickle Cell Disease
University of Illinois at Chicago
P2/3
B
(56)
ZINC SULFATE
Sickle Cell Disease
Indiana University
P2/3
B
(56)
Tocilizumab
Sickle Cell Disease
Assistance Publique - Hôpitaux de Paris
P3
CCC
(55)
Showing 26 to 50 of 122 assets
Previous
Page 2 of 5
Next